论文部分内容阅读
目的应用外源性心钠素 (ANP) ,观察其对肝硬化患者血浆内皮素 (ET)、血管紧张素Ⅱ (ATII)等缩血管物质的影响。方法应用心血通注射液 (心钠素 )治疗 4 1例肝硬化患者 ,用放免法分别检测治疗前后血浆ANP、ET、ATⅡ的水平 ,同时检测 2 0例健康人。结果肝硬化组比正常组血浆ANP、ET、ATⅡ水平明显升高 (P <0 0 5 ) ;肝硬化患者血浆ANP与ET呈负相关 ,与ATⅡ无显著相关。外源性心钠素能降低childA级和 /或B级ET、ATII的水平 (P <0 0 5 ,P <0 0 1) ,对childC级无抑制作用。结论肝硬化患者血管扩张因子与血管收缩因子之间失衡 ,促进腹水及门脉高压的形成 ,外源性心钠素能部分调节它门之间的紊乱关系 ,对肝硬化失代偿期的治疗有重要价值。
Objective To study the effect of exogenous atrial natriuretic peptide (ANP) on vasoactive substances such as endothelin (ET) and angiotensin Ⅱ (ATII) in patients with liver cirrhosis. Methods 41 cases of patients with cirrhosis were treated with XHXT (atrial natriuretic peptide), and plasma levels of ANP, ET and ATⅡ were measured by radioimmunoassay before and after treatment. Twenty healthy people were also detected. Results Plasma levels of ANP, ET and ATⅡ in patients with cirrhosis were significantly higher than those in patients with normal controls (P <0.05). There was a negative correlation between ANP and ET in patients with cirrhosis and no correlation with AT Ⅱ. Exogenous atrial natriuretic peptide can reduce the levels of childA and / or B ET and ATII (P <0.05, P <0.01), and has no effect on childC level. Conclusions The imbalance between vasodilators and vasoconstriction factors in cirrhotic patients promotes the formation of ascites and portal hypertension. Exogenous atrial natriuretic peptide can partly regulate the relationship between the disorders of its portal and the treatment of decompensated cirrhosis Have important value.